ABBISKO-B (02256) released its annual performance report. The revenue increased by 21.45% year-on-year to 612 million yuan.

ABBISKO-B(02256) released the annual performance for the financial year ending on December 31, 2025. The group achieved a revenue of 612 million yuan, a year-on-year increase of 21.45%; the comprehensive income attributable to the owners of the parent company was 23.698 million yuan, a year-on-year decrease of 53.46%; basic earnings per share were 0.09 yuan. We have achieved profits for the second consecutive year. For the financial year ending on December 31, 2025, the group's revenue was 6.121 billion yuan (including the authorized revenue from Merck), with a profit of 55.2 million yuan. We repurchased shares to enhance market confidence and shareholder value. On March 3, 2025, the Board approved the repurchase of shares with an amount not exceeding 200 million Hong Kong dollars to enhance market confidence and shareholder value. As of the financial year ending on December 31, 2025, the company had repurchased 10.29 million shares (1.51% of the total number of shares issued as of January 1, 2025), with a total amount involved of 84.7 million Hong Kong dollars. In 2024, the company also repurchased a total of 22.594 million shares, with a total amount involved of 68.7 million Hong Kong dollars. We have sufficient cash reserves on hand. As of December 31, 2025, our cash and bank balances (including fixed deposits of three months or more and cash and cash equivalents) were 2.27 billion yuan, an increase of 67.8 million yuan from December 31, 2024. The increase in cash was mainly due to the receipt of authorized revenue and an increase in interest-bearing bank borrowings.